Jazz Pharmaceuticals Plc Stock Price, News & Analysis

Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced it will release its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide business updates.

The webcast will be accessible through Jazz Pharmaceuticals' Investor Relations website, with dial-in numbers available for U.S. (+1 800 715 9871) and Ireland (+353 1800 943 926) participants. Interested parties are advised to register 15 minutes before the scheduled webcast.

Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, with a portfolio including therapies for sleep disorders, epilepsy, and cancer treatments.

Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chairman and CEO Bruce Cozadd will deliver a corporate presentation and business update on January 14, 2025, at 9:45 a.m. PST.

The presentation will be accessible via webcast through the Investors section of Jazz Pharmaceuticals' website, with a replay available for 30 days post-conference. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, particularly in sleep disorders, epilepsy, and cancer treatments. The company maintains its headquarters in Dublin, Ireland, with research, development, and manufacturing facilities across multiple countries.

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that CEO Bruce Cozadd plans to retire by the end of 2025, while continuing as Board Chair. The company's Board will conduct a comprehensive internal and external search for his successor, expected to conclude within 12 months.

Cozadd co-founded Jazz in 2003 and has served as CEO since 2009, transforming it into a global biopharmaceutical company with a focus on neuroscience and oncology. Under his leadership, the company grew to expect $4.0-4.1 billion in total revenue for 2024. Jazz currently employs approximately 2,800 people globally and maintains a commercialized portfolio with a differentiated pipeline of assets.

Jazz Pharmaceuticals (JAZZ) presented nine company-sponsored Epidiolex® (cannabidiol) posters at the American Epilepsy Society 2024 Annual Meeting. The presentations include real-world evidence from multiple studies showcasing the drug's effectiveness in treating rare epilepsies.

Key findings include: improvements in behavioral symptoms from the EpiCom trial; positive outcomes from the BECOME-TSC survey where 89% of caregivers plan to continue treatment; and results from the BECOME-LTC survey showing 85% of nurses reported reduced seizure frequency, with 49% noting over 50% reduction. The data also demonstrated Epidiolex's effectiveness in treating tuberous sclerosis complex (TSC), with median seizure reductions of 51%-87% in focal seizures and 44%-87% in total seizures.

Jazz Pharmaceuticals celebrates International Volunteers Day on December 5th, recognizing the global achievements of volunteers and the profound impact of volunteerism on society. This annual observance allows for reflection on community engagement efforts. Jazz Pharmaceuticals highlights its commitment to volunteerism and community engagement in its latest Corporate Sustainability and Social Impact Report. For more details, visit Jazz's profile on 3blmedia.com.

Jazz Pharmaceuticals announced that zanidatamab-hrii (Ziihera®) has been included in the NCCN Clinical Practice Guidelines as a category 2A treatment option for Biliary Tract Cancers (BTC). The drug, which received FDA accelerated approval on November 20, 2024, is now commercially available in the United States.

Ziihera is the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC. The approval was based on the HERIZON-BTC-01 clinical trial results, which showed a 52% objective response rate and median duration of response of 14.9 months. The drug is indicated for adults with previously treated, unresectable or metastatic HER2-positive BTC.

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced a webcast scheduled for December 11, 2024, at 4:30 p.m. ET to discuss Ziihera® (zanidatamab-hrii), their recently approved chemotherapy-free dual HER2-targeted bispecific antibody for biliary tract cancer (BTC). The presentation will cover clinical data, patient needs, and commercialization strategy.

The FDA granted accelerated approval to Ziihera on November 20, 2024, for treating adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC. Dr. Shubham Pant from MD Anderson Cancer Center will discuss data from the HERIZON-BTC-01 trial during the webcast.

Jazz Pharmaceuticals (JAZZ) announced presentations at two major medical conferences: the 2024 San Antonio Breast Cancer Symposium (SABCS) and the 66th American Society of Hematology (ASH) Annual Meeting. At SABCS, the company will present two abstracts focusing on Ziihera® (zanidatamab-hrii), including a Phase 3 trial design and new data from a Phase 1b/2 study in HER2-positive breast cancer patients.

At ASH, Jazz will showcase 13 abstracts, primarily featuring research on Vyxeos® and Defitelio®. The presentations include multiple Phase 3 trials and studies examining various combination therapies for acute myeloid leukemia (AML) and other blood cancers. This extensive research portfolio demonstrates Jazz's commitment to advancing cancer treatment options.

Jazz Pharmaceuticals announced FDA accelerated approval of Ziihera (zanidatamab-hrii) for treating adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). The approval is based on the HERIZON-BTC-01 trial results showing a 52% objective response rate and 14.9 months median duration of response. Ziihera is the first dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing, and continued approval may be contingent upon verification of clinical benefit.